Table 2.

Glycosylation gene SNPs significantly associated with ovarian cancer risk among Caucasian subjects

GeneSNPCase/control (829/941)MAF*PModelOR (95% CI)P§
FUT3rs2306969AAAGGG
Combined496/534289/35642/490.230.30D0.79 (0.64-0.97)0.024
Mayo only224/259143/18517/160.230.0130.85 (0.63-1.15)
Duke only272/275146/17125/330.230.370.76 (0.57-1.02)
FUT7rs10732706TTTCCC
Mayo only172/189170/21343/600.351.0A0.80 (0.64-1.00)0.049
GALNT1rs17647532TTTCCC
Combined678/757150/1621/200.100.002R0.07 (0.01-0.53)0.00017
Mayo only314/37870/711/120.100.00030.14 (0.02-1.14)
Duke only364/37980/910/80.100.35NA
GALNT2rs3213495AAAGGG
Mayo only313/33164/1054/80.120.92A0.62 (0.44-0.87)0.0053
GALNT6rs907352GGGCCC
Combined635/723172/20522/120.130.55R2.38 (1.09-5.19)0.024
Mayo only286/34988/10911/40.130.153.61 (0.96-13.5)
Duke only349/37484/9611/80.120.521.72 (0.63-4.72)
GALNT7rs934358CCCGGG
Combined522/548280/34227/500.220.72A0.80 (0.67-0.95)0.010
Mayo only252/274118/16515/230.210.780.70 (0.54-0.92)
Duke only270/274162/17712/270.230.820.84 (0.66-1.07)
MGAT5rs1257187AAAGGG
Combined571/684230/24327/140.160.14A1.27 (1.05-1.55)0.016
Mayo only265/334110/12210/60.160.161.21 (0.90-1.64)
Duke only306/350120/12117/80.160.501.32 (1.01-1.74)
ST3GAL3rs3828139TTTCCC
Combined243/238423/469160/2300.470.97R0.77 (0.60-0.98)0.035
Mayo only122/116187/23076/1160.470.160.78 (0.54-1.12)
Duke only121/122236/23984/1140.480.500.75 (0.53-1.07)
rs37460GGGCCC
Combined237/242426/462164/2330.480.67R0.78 (0.61-0.99)0.048
Mayo only120/119188/22777/1160.470.710.80 (0.56-1.15)
Duke only117/123238/23587/1170.480.820.77 (0.55-1.09)
  • * MAF estimated using both cases and controls.

  • P for testing departure from HWE among controls.

  • Genetic models (A, additive; D, dominant; R, recessive) with adjustment for age, geographic region, BMI, HRT use, oral contraceptive use, and parity/age at first birth.

  • § P for testing the genetic effects before multiplicity adjustment.

  • SNPs rs10732706 and rs3213495 genotyping in the Duke samples did not pass the quality control.